Title : The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Pub. Date : 2018 Apr

PMID : 29353886






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL. Cysteamine BCL2 apoptosis regulator Homo sapiens